menu
    • menu

    Company profile for Daiichi Sankyo

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. We provide innovative products and services in more than 20 countries around the world. With more than 100 years of scientific expertise, our company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients. Through the outstanding knowledge and commitment of our 15,000 employees worldwide, we crea...
    Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. We provide innovative products and services in more than 20 countries around the world. With more than 100 years of scientific expertise, our company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients. Through the outstanding knowledge and commitment of our 15,000 employees worldwide, we create innovative new and generic medicines, and new methods of drug discovery and delivery. We share a passion for innovation, as well as compassion for the patients around the world who are in need of our medicines.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Daiichi Sankyojapan Flag
    Country
    Country
    Japan
    Address
    Address
    3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo 103-8426
    Telephone
    Telephone
    +81-3-6225-1111
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.daiichisankyo.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/daiichi-sankyo
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/daiichisankyo?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI India

    Not Confirmed

    envelop Contact Supplier

    CPhI India

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    “Over 500 million syringes of our hyaluronic acid have been safely used worldwide”

    mic“Over 500 million syringes of our hyaluronic acid have been safely used worldwide”

    This week, SpeakPharma interviews Marie-Armelle Floc’h, Chief of Quality and Regulatory Affairs at HTL Biotechnology, a global leader in the development and the manufacturing of pharmaceutical-grade biopolymers headquartered in Javené, Brittany (France). Since 1992, HTL has pioneered the production of hyaluronic acid (HA) through proprietary biofermentation, achieving unmatched purity and consistency for applications in ophthalmology, dermatology and rheumatology. Floc’h highlights how HTL Biotechnology’s compelling portfolio of pharmaceutical-grade biopolymers is built on uncompromising quality standards. These standards have enabled the company to supply biopolymers for over 30 years without a single batch recall, firmly establishing its reputation for reliability and excellence. She also discusses the inauguration of HTL Biotechnology’s new sterile hyaluronic acid production unit — a major milestone that reinforces the company’s leadership in biopolymer manufacturing and enables the development of innovative formulations combining hyaluronic acid with thermo-sensitive active ingredients. This new capability opens the door to advanced biomedical applications where safety, stability and efficacy must be preserved without compromising the integrity of delicate molecules and which requires the highest quality standards. What distinguishes HTL Biotechnology’s biopolymer platforms in the market today? HTL Biotechnology has built its reputation on delivering pharmaceutical‑grade biopolymers (hyaluronic acid, polynucleotides and recombinant collagen) with unmatched purity and consistency. Since its founding in 1992, the company has focused on premium quality positioning. With more than 30 years of experience, HTL Biotechnology guarantees pharmaceutical-grade biopolymers of exceptional purity and exemplary consistency to our clients. We have had no batch recalls in 30 years, a record that underlines the rigor and reliability embedded in our processes. This was made possible by our fully-integrated site in France, where R&D laboratories, GMP manufacturing, quality control, and regulatory expertise are brought together under one roof. Such integration allows us to support our clients seamlessly throughout their product development journey, from early innovation through to global commercialization.Also, the inauguration of our new sterile hyaluronic acid production unit expands the possibilities for our HA to be used in advanced formulations with thermo-sensitive active ingredients, while upholding the uncompromising quality that defines HTL Biotechnology.Our operations are guided by internationally recognized standards, including ISO 13485 certification, which ensures the quality and safety required by medical device manufacturers worldwide.In addition, our Halal certification provides our customers with a significant advantage in accessing and expanding into markets where these requirements are essential for commercialization.Beyond certifications, our commitment to supporting global growth is reflected in the Drug Master Files we maintain across five continents, enabling our clients to accelerate product registration and bring innovative therapies to markets across the world more efficiently. By combining craftsmanship with pharmaceutical rigor, supported by state-of-the-art equipment and advanced bio-production methods, we ensure that every batch produced not only meets the strictest standards, but also delivers the reliability and consistency needed across the entire healthcare ecosystem. HIGHLIGHTS// Biopolymers with unmatched purity/record of no batch recalls/integrated facility in France/operations guided by global standards/new sterile HA unit for advanced formulations  Navigating the complex and evolving regulatory frameworks across global markets can be challenging for healthcare companies. Can you tell us more about how HTL Biotechnology supports its partners in this area? Regulatory support is part of our core premium services offer. We provide pharmaceutical regulatory support to ensure products meet the necessary compliance standards, so our partners can focus on their growth. Our dedicated regulatory professionals bring global and regional expertise, with a team specifically supporting customers in Asia. We offer personalized assistance adapted to their products and to the compliance standards of the target market. This includes personalized case-management support for regulatory file submissions with the concerned health authorities to minimize risks of refusal or delay, with the aim of achieving approval quickly and smoothly.Our offer for regulatory support continues beyond approval. We continuously monitor updates to regulations and provide post-commercialization support to our partners to help them manage any necessary regulatory updates.HIGHLIGHTS// Regulatory support offered as premium service/global and regional expertise/personalized case management for faster approvals/continuous regulatory support  How does HTL Biotechnology integrate sustainability and corporate responsibility into its operations? Sustainability is embedded in HTL Biotechnology’s strategic vision and day-to-day operations. In 2024, the company renewed its commitment to environmental responsibility by reinforcing its corporate social responsibility (CSR) roadmap. Tangible progress was made across multiple fronts: a 27 percent reduction in greenhouse gas emissions per kilogram of HA produced between 2021 and 2024, and a 34 percent reduction in water consumption per kilogram of HA since 2020. In 2024, we renewed the ISO 14001:2015 certification for its environmental management system, reflecting rigorous audit protocols and continual improvement cycles. All employees have been trained in the ISO 14001-certified environmental management system, and 78 percent of critical suppliers have signed HTL Biotechnology’s Responsible Purchasing Charter.These results reflect HTL Biotechnology’s structured and proactive approach to reducing its environmental footprint while maintaining the highest standards of quality and compliance.HIGHLIGHTS// Sustainability embedded in strategic vision/strong CSR roadmap with measurable progress/reduction in greenhouse gas emissions/responsible sourcing 

    Impressions: 97

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/over-500-million-syringes-of-our-hyaluronic-acid-have-been-safely-used-worldwide

    PharmaCompass
    04 Nov 2025
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    ReelPharmaA Full-Service API CompanyA Full-Service API Company

    A Full-Service API Company
    A Full-Service API Company

    reelA Full-Service API Company

    This PharmaReel showcases ChemWerth, a full-service generic API company with over 40 years of experience, offering cGMP-quality APIs through 30+ manufacturing partners across the US, EU, India, and China, backed by 550+ global filings, and expertise in new product development, compliance, and logistics.

    Impressions: 93

    read-more

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    CDMO Activity Tracker: Veranova, ChemExpress invest in ADC facilities; Cohance to set up oligonucleotide facility in India

    CDMO Activity Tracker: Veranova, ChemExpress invest in ADC facilities; Cohance to set up oligonucleotide facility in India

    The contract development and manufacturing organization (CDMO) sector has emerged as a key partner in new drug development. This was evident from the strategic investments, partnerships, and expansions witnessed in the third quarter (Q3) of 2025. Several CDMOs, such as Cohance Lifesciences, Fermion Oy, Axplora, AGC Pharma Chemicals invested in new projects. Others, including Veranova, Aenova, and Biosynth, expanded capacities, while Ofichem strengthened its footprint with the acquisition of Avivia BV. CDMOs like Fareva, Evonik, and Samsung Biologics forged strategic partnerships for growth. During Q3, the sector continued to adopt artificial intelligence (AI). This prompted the US Food and Drug Administration (FDA) to issue guidance that recognizes the increasing use of AI and data analytics in drug development.  View CDMO Activity Tracker for Q3 2025 (Free Excel Available) Cohance, Veranova invest in bioconjugation suites in US; ChemExpress inks ADC deal Earlier this year, Indian drugmaker Suven Pharmaceuticals Limited merged with  leading CDMO Cohance Lifesciences Limited. The merged entity — Cohance Lifesciences — has invested US$ 10 million in a current Good Manufacturing Practice (cGMP) bioconjugation suite at its subsidiary NJ Bio in Princeton, New Jersey.  NJ Bio is executing a major program for an existing innovator client with multiple antibody-drug conjugate (ADC) candidates. Cohance also announced an INR 230 million (approximately US$ 2.58 million) investment in a cGMP oligonucleotide facility at its Hyderabad (India) site. Veranova’s Devens (Massachusetts) site successfully passed a routine FDA cGMP surveillance inspection with a “No Action Indicated” (NAI) classification. Earlier, the company had initiated a US$ 50 million investment to expand its ADC and bioconjugate capabilities at its Devens site. This includes a 9,000-square-foot facility expansion with a new process development lab, two additional cGMP suites, and state-of-the-art bioconjugation development and manufacturing capabilities. These initiatives strengthen the site’s highly potent API (HPAPI) and ADC development and manufacturing capabilities. Biosynth has expanded its Berlin facility with a new GMP bioconjugation suite. The expansion supports the company’s manufacturing capabilities in conjugate vaccines, conjugate drugs, activated polyethylene glycol (PEGs), and polymer-based drug delivery excipients. ChemExpress, Mabwell Bioscience, and Insilico Medicine have entered into a strategic partnership to jointly develop a large ADC compound library and advance next-generation ADC candidates. The collaboration combines Mabwell’s antibody and ADC technology, Insilico’s AI-powered drug design platform, and ChemExpress’s expertise in linker-payload chemistry. Together, they aim to build a complete, AI-driven ADC development model that accelerates discovery, optimization, and commercialization. This partnership is expected to enhance R&D efficiency and deliver safer, more effective cancer treatments.  View CDMO Activity Tracker for Q3 2025 (Free Excel Available) Fermion, Axplora, Aenova increase API manufacturing capacities; ICE Pharma expands India facility Finnish CDMO Fermion Oy has launched a renovation project at its Hanko (Finland) production site to modernize its API manufacturing capabilities. This expansion is part of Fermion's broader strategy to increase production, enhance flexibility in the manufacturing of both existing and future pharmaceutical products, and enable potential contract manufacturing opportunities. German CDMO Axplora has announced a €6.5 million (approximately US$ 7.5 million) investment to expand its API manufacturing capacity at its Vizag site in India. This expansion aims to strengthen both production capabilities and supply chain resilience. India-based Aarti Pharmalabs has inaugurated the first phase of its greenfield manufacturing facility in Gujarat (India). This expansion aims to bolster Aarti's CDMO and contract manufacturing organization (CMO) services, targeting a revenue goal of INR 10 billion (approximately US$ 112 million). Snapdragon Chemistry, which was acquired by Cambrex in 2023, has expanded its Massachusetts facility to better support peptide drug development and manufacturing. With this upgrade, the company can now handle peptide projects from early development through full-scale manufacturing. Italy-headquartered ICE Pharma has expanded its Raichem facility in India. The new facility will enhance the production of ursodeoxycholic acid (UDCA), an API it derives from chicken bile. This expansion increases the site’s raw UDCA output by 120 metric tons annually. Spain-headquartered AGC Pharma Chemicals inaugurated a new advanced manufacturing plant in Barcelona, with an investment of €110 million (approximately US$ 128.3 million). The plant spans 7,500 square meters and integrates cutting-edge technologies to support the entire drug development lifecycle — from R&D to commercial manufacturing. This represents a 30 percent increase in the company’s production capacity and introduces a segment dedicated to HPAPIs. Germany-headquartered Aenova has launched a new hot melt extrusion platform at its Regensburg (Germany) site. This new equipment enables the production of advanced drug formulations, while handling all testing and quality checks in-house. The move strengthens Aenova’s capabilities in developing and manufacturing complex medications. US-based Cytovance Biologics has introduced in-house formulation development services, enhancing its role as a comprehensive partner for biologic drug developers. These services utilize quality-by-design principles to ensure speed, safety, and precision in current and future client programs.  View CDMO Activity Tracker for Q3 2025 (Free Excel Available)  Ofichem acquires Avivia BV; Evonik, Samsung Biologics form strategic collaborations Europe-based CDMO Ofichem Group announced the acquisition of Avivia BV, a formulation development company in the Netherlands. This acquisition is part of Ofichem’s strategy to become a fully integrated provider of development solutions across both drug substance and drug product, with a focus on complex formulations. Ofichem has also acquired Meribel Pharma Solutions’ site in Uppsala (Sweden) to strengthen its support for biotech innovators and expand its presence in the Nordic region.  Simtra BioPharma Solutions has acquired a 65-acre property near its Bloomington, Indiana (US) facility, adding over 300,000 square feet of potential expansion space. With this site, Simtra now has the flexibility to rapidly expand in the US. German specialty chemicals company Evonik is partnering with German biotech Ethris to develop and commercialize a next-generation lipid nanoparticle (LNP) platform for delivering nucleic acid therapies. Evonik will assist in formulation using Ethris’ SNaP LNP technology. The LNP market alone is projected to grow to US$2.3 billion by 2032. Luxembourg-headquartered Fareva has partnered with Zhaoke Ophthalmology to expand its footprint in China’s pharma market. Zhaoke will act as Fareva’s go-to partner for customers seeking pharmaceutical manufacturing in China. Samsung Biologics has signed a 1.8 trillion won (US$ 1.3 billion) manufacturing agreement with an undisclosed US-based drugmaker. And UK-based eXmoor Pharma has partnered with Anthony Nolan to provide end-to-end services for cell therapy developers.  View CDMO Activity Tracker for Q3 2025 (Free Excel Available)  Our view The global CDMO market, valued at around US$ 255 billion in 2025, is projected to grow to over US$ 465 billion by 2032. Significantly, about 60 percent of new drug approvals in the US and over 65 percent in Europe now involve CDMO support. The developments outlined above underscore the increasing role CDMOs are playing today in bringing about growth and innovation in the pharmaceutical industry.  
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 2471

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-chemexpress-invest-in-adc-facilities-cohance-to-set-up-oligonucleotide-facility-in-india

    #PharmaFlow by PHARMACOMPASS
    16 Oct 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Destiny-Lung06 Trial Begins: Enhertu Phase 3 For 1St-Line HER2
    Destiny-Lung06 Trial Begins: Enhertu Phase 3 For 1St-Line HER2

    30 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251030008969/en/DESTINY-Lung06-Phase-3-Trial-of-ENHERTU-Initiated-as-First-Line-Therapy-in-Patients-with-HER2-Overexpressing-Metastatic-Non-Squamous-Non-Small-Cell-Lung-Cancer

    BUSINESSWIRE
    30 Oct 2025
    Share Share
    ESMO: Daiichi, Merck Move Ovarian Cancer ADC Toward Pivotal Test
    ESMO: Daiichi, Merck Move Ovarian Cancer ADC Toward Pivotal Test

    20 Oct 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/esmo-daiichi-merck-power-ovarian-cancer-adc-toward-pivotal-trial-after-passing-phase-2-test

    FIERCE BIOTECH
    20 Oct 2025
    Share Share
    DS-3939 Shows Promising Activity in Advanced Solid Tumors
    DS-3939 Shows Promising Activity in Advanced Solid Tumors

    19 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251019911815/en/DS-3939-Shows-Promising-Preliminary-Clinical-Activity-in-Patients-with-Advanced-Solid-Tumors-in-Phase-12-Trial

    BUSINESSWIRE
    19 Oct 2025
    Share Share
    Datroway Shows 5-Month Survival Gain Over Chemotherapy
    Datroway Shows 5-Month Survival Gain Over Chemotherapy

    19 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251019553773/en/DATROWAY-datopotamab-deruxtecan-dlnk-demonstrated-unprecedented-median-overall-survival-improvement-of-five-months-vs.-chemo-as-1st-line-treatment-for-patients-with-metastatic-triple-negative-breast-cancer-for-whom-immunotherapy-was-not-an-option

    BUSINESSWIRE
    19 Oct 2025
    Share Share
    ESMO: Datroway Data Edge Out Trodelvy In First TROP2 Face-Off
    ESMO: Datroway Data Edge Out Trodelvy In First TROP2 Face-Off

    19 Oct 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/az-daiichi-datroway-outshines-gilead-trodelvy-first-global-trop2-showdown

    FIERCE PHARMA
    19 Oct 2025
    Share Share
    Enhertu Cuts Recurrence Risk By 53% In High-Risk Her2 Cancer
    Enhertu Cuts Recurrence Risk By 53% In High-Risk Her2 Cancer

    18 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251018027927/en/ENHERTU-fam-trastuzumab-deruxtecan-nxki-reduced-the-risk-of-disease-recurrence-or-death-by-53-vs.-T-DM1-in-patients-with-high-risk-HER2-positive-early-breast-cancer-following-neoadjuvant-therapy-in-DESTINY-Breast05-Phase-III-trial

    BUSINESSWIRE
    18 Oct 2025
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Daiichi Sankyo Co Ltd and get a quotation

    Daiichi Sankyo Co Ltd is a supplier offers 78 products (APIs, Excipients or Intermediates).

    Find a price of Ofloxacin bulk with CEP offered by Daiichi Sankyo Co Ltd

    Find a price of Olmesartan Medoxomil bulk with CEP offered by Daiichi Sankyo Co Ltd

    Find a price of Pravastatin bulk with CEP offered by Daiichi Sankyo Co Ltd

    Find a price of Codeine bulk with JDMF offered by Daiichi Sankyo Co Ltd

    Find a price of Codeine Phosphate bulk with JDMF offered by Daiichi Sankyo Co Ltd

    Find a price of Deruxtecan bulk with DMF offered by Daiichi Sankyo Co Ltd

    Find a price of Human Ghrelin bulk with DMF offered by Daiichi Sankyo Co Ltd

    Find a price of Hydromorphone Hydrochloride bulk with JDMF offered by Daiichi Sankyo Co Ltd

    Find a price of Levodopa bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Oxycodone Hydrochloride bulk with JDMF offered by Daiichi Sankyo Co Ltd

    Find a price of MUCOPOLYSACCHARIDE POLYSULFATE DRUG SUBSTANCE bulk with DMF offered by Daiichi Sankyo Co Ltd

    Find a price of 2-Naphthalenepropanoic Acid bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Benfluorexum bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Carperitide bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Cefmetazole bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Cefmetazole Sodium bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Cefpodoxime Proxetil bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Cetraxate bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Edoxaban Tosylate bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Enkephalin, Methionine bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Faropenem bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Hydrochlorothiazide bulk offered by Daiichi Sankyo Co Ltd

    Find a price of L-VALINE bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Levofloxacin bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Levofloxacin Hydrochloride bulk offered by Daiichi Sankyo Co Ltd

    Find a price of MALOTILATE bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Managlinat Dialanetil bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Mepirizole bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Nimustine bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Ofloxacin bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Olmesartan Medoxomil bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Pantethine bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Phenylalanine bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Pravastatin bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Temocapril Hydrochloride bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Tomopenem bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Tranexamic Acid bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Troglitazone bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Tryptophan bulk offered by Daiichi Sankyo Co Ltd

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN EDOGAWA-KU, TOKYO, JAPAN. bulk offered by Daiichi Sankyo Co Ltd

    Find a price of CS-758 DRUG PRODUCT bulk offered by Daiichi Sankyo Co Ltd

    Find a price of DX-8951F DRUG SUBSTANCE bulk offered by Daiichi Sankyo Co Ltd

    Find a price of DL 8280 MEFOXACIN A & PLACEBO TABS bulk offered by Daiichi Sankyo Co Ltd

    Find a price of DS-1594B DRUG PRODUCT bulk offered by Daiichi Sankyo Co Ltd

    Find a price of SUN N4057 DRUG SUBSTANCE bulk offered by Daiichi Sankyo Co Ltd

    Find a price of SUN13834 DRUG SUBSTANCE bulk offered by Daiichi Sankyo Co Ltd

    Find a price of DS-4152 DRUG SUBSTANCE bulk offered by Daiichi Sankyo Co Ltd

    Find a price of DX-619 DRUG SUBSTANCE bulk offered by Daiichi Sankyo Co Ltd

    Find a price of CS-003 DRUG PRODUCT bulk offered by Daiichi Sankyo Co Ltd

    Find a price of DT-5621 DRUG SUBSTANCE bulk offered by Daiichi Sankyo Co Ltd

    Find a price of PANTOSIN 200 MG TABLETS bulk offered by Daiichi Sankyo Co Ltd

    Find a price of DATICHI PHARMACEUTICAL CO LTD DU-6859A bulk offered by Daiichi Sankyo Co Ltd

    Find a price of PRODUCTION TECHNOLOGY RESEARCH LABS., EDOGAWA-KU, TOKYO, JAPAN bulk offered by Daiichi Sankyo Co Ltd

    Find a price of CS-505 DRUG SUBSTANCE bulk offered by Daiichi Sankyo Co Ltd

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN SHIZUOKA JAPAN. bulk offered by Daiichi Sankyo Co Ltd

    Find a price of POLYSULFATED GLYCOSAMINOGLYCAN (PSGAG) bulk offered by Daiichi Sankyo Co Ltd

    Find a price of CS-011 DRUG PRODUCT bulk offered by Daiichi Sankyo Co Ltd

    Find a price of DZ-697B DRUG SUBSTANCE bulk offered by Daiichi Sankyo Co Ltd

    Find a price of CS-834 DRUG PRODUCT bulk offered by Daiichi Sankyo Co Ltd

    Find a price of DK-507K DRUG SUBSTANCE bulk offered by Daiichi Sankyo Co Ltd

    Find a price of SUN N 8075 DRUG SUBSTANCE bulk offered by Daiichi Sankyo Co Ltd

    Find a price of BULK CS-045 ORAL HYPOGLYCEMIC bulk offered by Daiichi Sankyo Co Ltd

    Find a price of CS-758 DRUG SUBSTANCE bulk offered by Daiichi Sankyo Co Ltd

    Find a price of CS-505 DRUG PRODUCT bulk offered by Daiichi Sankyo Co Ltd

    Find a price of MIX-RR bulk offered by Daiichi Sankyo Co Ltd

    Find a price of DS-1594B DRUG SUBSTANCE bulk offered by Daiichi Sankyo Co Ltd

    Find a price of DE-310 DRUG SUBSTANCE bulk offered by Daiichi Sankyo Co Ltd

    Find a price of SUN13837 DRUG SUBSTANCE bulk offered by Daiichi Sankyo Co Ltd

    Find a price of CS-780 DRUG PRODUCT bulk offered by Daiichi Sankyo Co Ltd

    Find a price of DW-908E DRUG SUBSTANCE bulk offered by Daiichi Sankyo Co Ltd

    Find a price of CS-834 DRUG SUBSTANCE bulk offered by Daiichi Sankyo Co Ltd

    Find a price of PARENTERAL FORMULATION FACILITY IN OSAKA, JAPAN. bulk offered by Daiichi Sankyo Co Ltd

    Find a price of CS-003 DRUG SUBSTANCE bulk offered by Daiichi Sankyo Co Ltd

    Find a price of FACILITIES AND OPERATING PROCEDURES IN HIRATSUKA-SHI, JAPAN bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Glycosaminoglycan bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Mirogabalin Besylate bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Pentosan Polysulfate Sodium bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Edoxabantosylate hydrate bulk offered by Daiichi Sankyo Co Ltd

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search